Use of low molecular weight thrombin inhibitor
US6462021B1 · kind B1 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 6, 2000 |
| Grant date | Oct 8, 2002 |
| Priority date | — |
| Expiry date | Nov 6, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of ischemic disorders in patients having, or at risk of, non-valvular atrial fibrillation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.